Aldeyra Therapeutics financials
$1.32+13.79%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$5.9M | -$3.5M | -$6.7M | -$8.0M | -$10.2M | -$10.4M | -$16.6M | -$16.1M | -$18.0M | -$9.4M | -$6.1M | -$9.6M |
| Net income | -$5.5M | -$3.5M | -$6.5M | -$7.7M | -$9.8M | -$9.9M | -$15.8M | -$15.1M | -$16.8M | -$8.1M | -$4.8M | -$8.2M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.09 | $-0.06 | $-0.11 | $-0.13 | $-0.16 | $-0.17 | $-0.27 | $-0.25 | $-0.28 | $-0.14 | $-0.08 | $-0.14 |
| EBITDA | -$5.8M | -$3.5M | -$6.6M | -$7.9M | -$10.1M | -$10.4M | -$16.5M | -$16.1M | -$17.9M | -$9.3M | -$6.0M | -$9.5M |
| Operating cash flow | -$4.6M | -$5.1M | -$5.3M | -$7.0M | -$8.6M | -$12.5M | -$12.0M | -$8.0M | -$13.2M | -$10.0M | $500.4K | -$8.0M |
| Free cash flow | -$4.6M | -$5.1M | -$5.3M | -$7.0M | -$8.6M | -$12.5M | -$12.0M | -$8.0M | -$13.2M | -$10.0M | $500.4K | -$8.0M |
| Diluted shares | 60.3M | 60.3M | 60.2M | 60.1M | 60.0M | 59.9M | 59.6M | 59.5M | 59.4M | 59.4M | 59.2M | 59.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $45.1M | $65.0M | $70.0M | $59.3M | $41.2M | $50.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $16.0M | $40.7M | $39.7M |
| Total debt | $0.00 | $15.3M | $15.2M | $15.2M | $15.1M | $15.1M |
| Total assets | $47.5M | $66.5M | $72.1M | $77.8M | $85.0M | $93.2M |
| Total liabilities | $9.7M | $24.3M | $27.8M | $28.6M | $29.7M | $29.6M |
| Shareholders' equity | $37.9M | $42.2M | $44.3M | $49.2M | $55.3M | $63.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology